株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大日本住友製薬の製品パイプライン分析

Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 321961
出版日 ページ情報 英文 103 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
大日本住友製薬の製品パイプライン分析 Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 103 Pages
概要

大日本住友製薬では中枢神経系(CNS)、心血管系、糖尿病、癌、感染症などの領域における様々なファーマシューティカル製品を開発・製造・商品化しています。また、動物用医薬品、食品添加物、診断用薬、研究用材料等の提供、さらに研究本部では革新的な新薬研究を行っています。

当レポートでは、大日本住友製薬 における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

大日本住友製薬 の基本情報

  • 大日本住友製薬 の概要
  • 主要情報
  • 企業情報

大日本住友製薬 :R&Dの概要

  • 主な治療範囲

大日本住友製薬 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

大日本住友製薬 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 登録申請前の製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

大日本住友製薬 :薬剤プロファイル

  • amrubicin hydrochloride
  • blonanserin
  • droxidopa
  • lurasidone hydrochloride
  • ranirestat
  • vatiquinone
  • afacifenacin
  • DSP-6952
  • obeticholic acid
  • zonisamide
  • EPI-589
  • WT-2725
  • WT-4869
  • DSP-0011
  • DSR-6434
  • NEP-28
  • SM-276001
  • SM-295291
  • SM-324405
  • SM-369926
  • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
  • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
  • Small Molecules to Activate Translocator Protein for Anxiety
  • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
  • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
  • Small Molecules to Target Ras Signaling Pathway for Cancer
  • Apoptosis Inhibitor Of Macrophages
  • HLS-001
  • Small Molecule to Antagonize GCGR for Type 2 Diabetes
  • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
  • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
  • Small Molecules to Inhibit CaMKII for Undisclosed Indication
  • Small Molecules to Inhibit mPGES-1 for Inflammation

大日本住友製薬 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

大日本住友製薬 :最新のパイプライン情報

大日本住友製薬 :開発が休止されたプロジェクト

大日本住友製薬 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • emapunil
    • rafabegron
    • ceftaroline fosamil
    • DSP-0565
    • DSP-3025
    • DSP-7238
    • DSP-9599
    • KGA-3235
    • limaprost
    • rafabegron
    • ranirestat
    • resequinil
    • rimacalib
    • SEP-225425
    • SEP-226332
    • SEP-227162
    • SEP-227900
    • SMP-028
    • SMP-797

大日本住友製薬 :企業理念

大日本住友製薬 :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08194CDB

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016', provides an overview of the Sumitomo Dainippon Pharma Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sumitomo Dainippon Pharma Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sumitomo Dainippon Pharma Co Ltd
  • The report provides overview of Sumitomo Dainippon Pharma Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sumitomo Dainippon Pharma Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sumitomo Dainippon Pharma Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sumitomo Dainippon Pharma Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sumitomo Dainippon Pharma Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sumitomo Dainippon Pharma Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sumitomo Dainippon Pharma Co Ltd Snapshot
    • Sumitomo Dainippon Pharma Co Ltd Overview
    • Key Facts
  • Sumitomo Dainippon Pharma Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products Glance
    • Sumitomo Dainippon Pharma Co Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities <
      li>Phase I Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co Ltd - Drug Profiles
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blonanserin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-0011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-1200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-6952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-7888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-17759 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-6434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-71167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-98776 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPI-589 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HLS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEP-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-276001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit mPGES-1 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Ras Signaling Pathway for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SMP-304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WT-2725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WT-4869 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zonisamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Analysis
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Target
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Route of Administration
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Molecule Type
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action
  • Sumitomo Dainippon Pharma Co Ltd - Dormant Projects
  • Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ceftaroline fosamil
      • DSP-0565
      • DSP-3025
      • DSP-7238
      • DSP-9599
      • emapunil
      • indiplon
      • KGA-3235
      • limaprost
      • rafabegron
      • ranirestat
      • razupenem
      • resequinil
      • rimacalib
      • SEP-225425
      • SEP-226332
      • SEP-227162
      • SEP-227900
      • SMP-028
      • SMP-797
  • Sumitomo Dainippon Pharma Co Ltd - Company Statement
  • Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sumitomo Dainippon Pharma Co Ltd, Key Facts
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pre-Registration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase III, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase II, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase I, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Preclinical, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Discovery, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Target, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Molecule Type, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Dormant Developmental Projects,2016
  • Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products, 2016
  • Sumitomo Dainippon Pharma Co Ltd, Other Locations
  • Sumitomo Dainippon Pharma Co Ltd, Subsidiaries

List of Figures

  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Indication, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Target, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Molecule Type, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top